Patients with malignant peritoneal mesothelioma research hub

INTERACT MESO: Intraperitoneal Paclitaxel for Patients with Primary Malignant Peritoneal Mesothelioma – a Phase I/II Dose Escalation and Safety Study

This study, called INTERACT MESO, is looking at a new way to give medicine for a type of cancer called malignant peritoneal mesothelioma. It's an early-stage study to find the best dose and check the safety of a drug called paclitaxel, given directly into the tummy area.